BRIEF-GSK CEO says to decide future of Lucozade, Ribena by mid-year

LONDON Wed Feb 6, 2013 7:44am EST

LONDON Feb 6 (Reuters) - GlaxoSmithKline Plc : * CEO says all options on table for Lucozade and Ribena * CEO says aims to conclude Lucozade and Ribena review by mid-2013 * CEO says has very low appetite for acquisitions * CEO says has very much focused on organic growth * CEO declines to comment in detail on job impact of latest restructuring * CEO says much of change in research and development, manufacturing involves

new processes rather than job cuts * CEO says likely to be some job losses in Europe due to pricing pressures * CEO says looking for commercialisation partner for new diabetes drug albiglutide

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.